Drug Profile
Research programme: G protein-coupled receptor modulators - Pfizer/Eli Lilly and Company
Alternative Names: GPCR modulators - Pfizer/Eli Lilly and CompanyLatest Information Update: 16 Mar 2022
Price :
$50
*
At a glance
- Originator Arena Pharmaceuticals; Eli Lilly and Company
- Class
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cardiovascular disorders; CNS disorders
Most Recent Events
- 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
- 24 Jun 2002 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 24 Jun 2002 Discontinued - Preclinical for CNS disorders in USA (unspecified route)